An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome
Latest Information Update: 07 Mar 2025
At a glance
- Drugs Trofinetide (Primary)
- Indications Rett syndrome
- Focus Adverse reactions; Pharmacokinetics
- Acronyms DAFFODIL
- Sponsors Acadia Pharmaceuticals
Most Recent Events
- 05 Mar 2025 Results presented in an Acadia Pharmaceuticals Media Release.
- 05 Mar 2025 According to an Acadia Pharmaceuticals media release, results of DAFFODIL, LAVENDER, LILAC-1 and LILAC-2 studies supported the FDA approval of DAYBUE in adults and pediatric patients two years of age or older.
- 05 Mar 2025 According to an Acadia Pharmaceuticals media release, results of this study published in the journal Med.